Research
Hormonal
Glucagon-like 1 receptor antagonists and sodium-glucose co-transporter 2 inhibitors play a role in secondary prevention of atherosclerotic cardiovascular disease.
These agents may be recommended for secondary prevention in diabetic patients with cardiovascular risks.
StrongSupportsmedium confidence
glucagon-like 1 receptor antagonists and sodium-glucose co-transporter 2 inhibitors play a role in secondary prevention of atherosclerotic cardiovascular disease.
Why this rating
Supported by recent large-scale cardiovascular outcome trials.
Source
Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Anna Pietraszek · Current Drug Safety · 2020
Meta-analysisCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →